ZEPATIER is a prescription medicine used with or without ribavirin to treat chronic (long-lasting) hepatitis C (hep C) genotypes 1 or 4 infection in adults. See important information below including the risk of hepatitis B virus reactivation.

 

ZEPATIER
and You

ZEPATIERand You

Models

Which storyline fits you best?

I am a patient with hep C genotypes 1 or 4 who has:
Never been treated
ZEPATIER is proven to cure chronic
hep C in patients who
are new to
treatment. Cure means the hep C
virus is not detected in
the blood
when measured 3 months after
treatment is completed.
Genotype 1
95cured
%

In a clinical study,

95% (273 of 288 patients) of patients

with genotype 1 chronic hep C infection
who had no prior treatment were cured with

12 weeks of once-daily ZEPATIER.

Genotype 4
97cured
%

Across clinical studies,

97% (64 of 66 patients) of patients

with genotype 4 chronic hep C infection

who had no prior treatment were cured with

12 weeks of once-daily ZEPATIER.

Tried certain hep C
treatments in the past
ZEPATIER is proven to cure chronic
hep C in patients who
have not been
cured by certain other hep C
treatments in the past.
Cure means
the hep C virus is not detected in the
blood when measured
3 months after
treatment is completed.
Advances in hep C medicines have improved today's treatments, making the time of treatment shorter and sometimes easier to take. If you have tried certain other hep C treatments in the past that did not cure your chronic hep C, ZEPATIER® (elbasvir and grazoprevir) may be right for you.
Genotype 1
94cured
%
- 
97cured
%

Among patients with genotype 1 hep C infection who were previously treated with interferon and ribavirin, 94% (90 of 96 patients) were cured with 12 weeks of once-daily ZEPATIER and 97% (93 of 96 patients) were cured with 16 weeks of once-daily ZEPATIER taken with ribavirin.

96cured
%

In a separate study of patients with genotype 1 hep C who were previously treated with medicines like Incivek®, Olysio®, or Victrelis® in combination with peginterferon and ribavirin, 96% (76 of 79 patients) were cured with 12 weeks of once-daily ZEPATIER taken with ribavirin.

Genotype 4
100cured
%

Among patients with genotype 4 hep C infection who
were previously treated with interferon and ribavirin for hep C,
100% (8 of 8 patients) were cured with 16 weeks of once-daily
ZEPATIER taken with ribavirin.

HIV
ZEPATIER can cure chronic hep C
genotypes 1 or 4
in patients with
HIV. Cure means the hep C virus is
not detected in the
blood when
measured 3 months after treatment
is completed.

Like many people, you might be facing other health conditions in addition to the challenges that are brought on by hep C. About 1 out of every 4 people in the United States who have HIV also have hep C. If you have hep C and HIV, it's especially important to get hep C treatment to protect your liver from further damage. Liver problems can progress more quickly when you have HIV.

People with both chronic hep C and HIV can take ZEPATIER to treat their hep C. Make sure to tell your health care provider if you have HIV along with hep C. Tell your health care provider about all of your health conditions and all the medicines you are taking.

Genotype 1
95cured
%

In a clinical study, 95% (179 of 189 patients)
of patients
with genotype 1 hep C and HIV
who had not taken a medicine
before to treat
their hep C were cured with 12 weeks of

once-daily ZEPATIER.

Severe kidney disease
ZEPATIER can cure chronic hep C
genotypes 1 or 4 in patients with

severe kidney disease. Cure means
the hep C virus is not detected in
the
blood when measured 3 months after
treatment is completed.

Along with managing your hep C, you might also have severe kidney disease or be on dialysis. ZEPATIER is processed and cleared from the body through the liver. It is not cleared through the kidneys and can be taken by people with severe kidney disease.

Genotype 1
94cured
%

In a clinical study, 94% (115 of 122 patients) of patients
with genotype 1 hep C infection and severe kidney
disease, including people who were previously treated for
hep C as well as people who were not, were cured

with 12 weeks of once-daily ZEPATIER.

Request more information about ZEPATIER® (elbasvir and grazoprevir)
Models



Please orient your device to the portrait position to return to the site

 

Important Safety Information

Before starting treatment with ZEPATIER® (elbasvir and grazoprevir), your health care provider will do blood tests to check for hepatitis B virus infection. If you have ever had hepatitis B virus infection, the hepatitis B virus could become active again during or after treatment of hep C virus infection with ZEPATIER. This is called hepatitis B virus reactivation, and it may cause serious liver problems including liver failure and death. Your health care provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop taking ZEPATIER.

Important Safety Information continued below

ZEPATIER is not for people with certain liver problems. Before taking ZEPATIER, tell your health care provider about all of your medical conditions, including if you have ever had hepatitis B virus infection or have liver problems other than hep C. Also tell your health care provider if you have ever taken any medicine for hep C, have HIV, or have had or are waiting for a liver transplant.

If you are nursing, pregnant, or trying to get pregnant, tell your health care provider. It is not known if ZEPATIER will harm your unborn baby or pass to your baby through breast milk. If you take ZEPATIER with ribavirin, be sure you read the Medication Guide for ribavirin, especially the important pregnancy, contraception, and infertility information.

Tell your health care provider about all of the medicines you take. ZEPATIER may affect how other medicines work, and other medicines may affect how ZEPATIER works. Some medicines cannot be taken with ZEPATIER. Your health care provider can tell you if it is safe to take ZEPATIER with other medicines.

ZEPATIER may cause increases in your liver-related blood tests, which could be a sign of serious liver problems. Your health care provider will do blood tests to check your liver before and during treatment with ZEPATIER. Tell your health care provider right away if you get any of the following symptoms or if they get worse during treatment with ZEPATIER: loss of appetite, nausea and vomiting, feeling tired or weak, yellowing of your skin or eyes, or color changes in your stool.

In clinical studies, common side effects of ZEPATIER included: feeling tired, headache, and nausea. When ZEPATIER was taken with ribavirin, common side effects also included low red blood cell counts (called anemia).

What is ZEPATIER?

ZEPATIER is a prescription medicine used to treat chronic (long-lasting) hepatitis C (hep C) genotypes 1 or 4 infection in adults. ZEPATIER may sometimes be given with another medicine called ribavirin.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call
1-800-FDA-1088.

Before taking ZEPATIER® (elbasvir and grazoprevir), please read the accompanying Patient Information, including information about the risk of the hepatitis B virus (HBV) becoming active again in patients who have ever had HBV infection, and discuss it with your doctor. The Prescribing Information also is available.

Questions about ZEPATIER?
Call 844-ZEPATIER (844-937-2843)
for more information.

Important Safety Information continued below